Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor
/PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute...